



**AC (DOXOrubicin/Cyclophosphamide) Every 21
Days Course**

page 1 of 2

INDICATION:	REFERENCES:	NCCN SUPPORTIVE CARE:
Adjuvant	<ol style="list-style-type: none">1. NCCN Clinical Practice Guidelines in Oncology™ Breast Cancer. V.2.2012.2. Romond EH, et al. <i>N Engl J Med.</i> 2005;353(16):1673-84.^b	<ol style="list-style-type: none">1. <i>Emetic Risk:</i> Day 1 High2. <i>Fever Neutropenia Risk:</i> Intermediate

CHEMOTHERAPY REGIMEN

21-day cycle for 4 cycles

- **DOXOrubicin** 60 mg/m² IV Push on Day 1
- See *Safety Parameters and Special Instructions* for information on slow IV Push administration.
- **Cyclophosphamide** 600 mg/m² IV over 30 minutes on Day 1
- Oral hydration is strongly encouraged with cyclophosphamide; poorly hydrated patients may need supplemental IV hydration. Patients should attain combined oral and IV hydration of 2 – 3 L/day on day of chemotherapy. See *Other Supportive Therapy* for example of IV hydration.

This course is 4 cycles of AC (DOXOrubicin/cyclophosphamide) Every 21 Days.

PACLitaxel Weekly is initiated following completion of this course.

Please see Order Template BRS6b for PACLitaxel Weekly course.

SUPPORTIVE CARE

Antiemetic therapy (See www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf)

Days 1 – 4

- 5-HT3 antagonist:
Dolasetron 100 mg PO Day 1
OR
Granisetron 2 mg PO daily or 1 mg PO BID or 0.01 mg/kg (maximum 1 mg) IV daily Day 1 or transdermal patch as 3.1 mg/24 hours patch (containing 34.3 mg granisetron total dose) applied approximately 24 – 48 hours prior to first dose of chemotherapy; maximum duration of patch is 7 days
OR
Ondansetron 16 – 24 mg PO or 8 – 24 mg (maximum 32 mg/day) IV Day 1
OR
Palonosetron 0.25 mg IV Day 1
- AND
- Steroid:
Dexamethasone 12 mg PO/IV Day 1, then 8 mg PO Days 2 – 4 (with aprepitant 125 mg PO or fosaprepitant 115 mg IV Day 1)
OR
Dexamethasone 12 mg PO/IV Day 1, 8 mg PO Day 2, then 8 mg PO BID Days 3 – 4 (with fosaprepitant 150 mg IV Day 1)
AND
- NK1 antagonist:
Aprepitant 125 mg PO or fosaprepitant 115 mg IV Day 1, aprepitant 80 mg PO Days 2 – 3
OR
Fosaprepitant 150 mg IV Day 1
- ± Lorazepam 0.5 – 2 mg PO/IV or sublingual every 4 or every 6 hours as needed Days 1 – 4
- ± H₂ blocker or proton pump inhibitor

Template continued on page 2

NCCN Chemotherapy Order Templates (NCCN Templates®) are peer-reviewed statements of the consensus of its authors derived from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) regarding their views of currently accepted approaches to treatment. An NCCN Template does not constitute an order. Any clinician seeking to treat a patient using the NCCN Templates® is expected to use independent medical judgment in the context of individual clinical circumstances of a specific patient's care or treatment. NCCN disclaims all warranties, express or implied including, without limitation, the implied warranties of merchantability and fitness for a particular purpose. NCCN does not warrant the accuracy, currency, or completeness of the NCCN Templates or make any representation regarding the use or the results of the use of the NCCN Templates in treatment. In no event shall NCCN or its members be liable for any damages including, without limitation, incidental, indirect, special, punitive, or consequential damages arising out of or in connection with the use of the NCCN Templates including, without limitation, loss of life, loss of data, loss of income or profit, losses sustained as a result of any injury to any person, or loss or damage to property or claims of third parties.



AC (DOXOrubicin/Cyclophosphamide) Every 21 Days Course

page 2 of 2

PRN for breakthrough: All patients should be provided with at least one medication for breakthrough emesis. Choose a medication in a different category (or drug class) than scheduled antiemetics. Please consult the NCCN Clinical Practice Guidelines in Oncology™ Antiemesis for appropriate antiemetic therapy.

Myeloid growth factor therapy (See www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf)

CSFs may be considered for primary prophylaxis based on FN risk of chemotherapy regimen. For more information on prophylaxis of FN, refer to NCCN Clinical Practice Guidelines in Oncology™ Myeloid Growth Factors and Appendix C to the NCCN Chemotherapy Order Templates.

Other Supportive Therapy

- For cyclophosphamide: *Example of recommended hydration:* Sodium chloride 0.9% infused IV at a rate of 1.5 – 3 mL/kg/hour for a total of 500 mL on day of chemotherapy.

MONITORING AND HOLD PARAMETERS

- CBC with differential should be assessed as clinically indicated for potential dose modification.
- For DOXOrubicin:
 - DOXOrubicin is an anthracycline. Cumulative anthracycline dosage should be monitored.
 - Ejection fraction should be assessed prior to initiation of treatment and as clinically indicated.
 - Liver function should be assessed to each cycle for potential dose modification.
- For cyclophosphamide: Renal function should be assessed as clinically indicated for potential dose modification.

SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS

- For DOXOrubicin:
 - **DOXOrubicin is a vesicant.**
 - This agent is administered IV Push. The preferred IV Push method for a vesicant is administration through the side port of a freely flowing IV; alternatively, the drug can be administered via direct IV push.
- For aprepitant and fosaprepitant: Refer to Appendix D for specific information regarding associated drug interactions.

NCCN Chemotherapy Order Templates (NCCN Templates®) are peer-reviewed statements of the consensus of its authors derived from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) regarding their views of currently accepted approaches to treatment. An NCCN Template does not constitute an order. Any clinician seeking to treat a patient using the NCCN Templates® is expected to use independent medical judgment in the context of individual clinical circumstances of a specific patient's care or treatment. NCCN disclaims all warranties, express or implied including, without limitation, the implied warranties of merchantability and fitness for a particular purpose. NCCN does not warrant the accuracy, currency, or completeness of the NCCN Templates or make any representation regarding the use or the results of the use of the NCCN Templates in treatment. In no event shall NCCN or its members be liable for any damages including, without limitation, incidental, indirect, special, punitive, or consequential damages arising out of or in connection with the use of the NCCN Templates including, without limitation, loss of life, loss of data, loss of income or profit, losses sustained as a result of any injury to any person, or loss or damage to property or claims of third parties.